215 related articles for article (PubMed ID: 10606257)
1. Oral fluoropoyrimidines.
Hoff PM; Royce M; Medgyesy D; Brito R; Pazdur R
Semin Oncol; 1999 Dec; 26(6):640-6. PubMed ID: 10606257
[TBL] [Abstract][Full Text] [Related]
2. New drugs in therapy of colorectal cancer: preclinical studies.
Rustum YM; Cao S
Semin Oncol; 1999 Dec; 26(6):612-20. PubMed ID: 10606254
[TBL] [Abstract][Full Text] [Related]
3. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
Hoff PM
Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
[TBL] [Abstract][Full Text] [Related]
4. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents.
Hoff PM; Pazdur R
Semin Oncol; 1999 Dec; 26(6 Suppl 18):52-6. PubMed ID: 10892578
[TBL] [Abstract][Full Text] [Related]
5. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
6. Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio RB
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
[TBL] [Abstract][Full Text] [Related]
7. [Fluorinated pyrimidines in oral treatment of advanced colorectal cancer].
Todnem K; Harboe K; Zotova L; Lind A; Ogreid D
Tidsskr Nor Laegeforen; 2000 Sep; 120(23):2781-5. PubMed ID: 11107924
[TBL] [Abstract][Full Text] [Related]
8. Fluoropyrimidines: a critical evaluation.
Brito RA; Medgyesy D; Zukowski TH; Royce ME; Ravandi-Kashani F; Hoff PM; Pazdur R
Oncology; 1999 Jul; 57 Suppl 1():2-8. PubMed ID: 10436410
[TBL] [Abstract][Full Text] [Related]
9. Oral fluoropyrimidines in colorectal cancer.
Van Cutsem E; Peeters M
Semin Oncol; 2000 Oct; 27(5 Suppl 10):91-5. PubMed ID: 11049039
[No Abstract] [Full Text] [Related]
10. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.
Sobrero A; Guglielmi A; Grossi F; Puglisi F; Aschele C
Semin Oncol; 2000 Oct; 27(5 Suppl 10):72-7. PubMed ID: 11049035
[No Abstract] [Full Text] [Related]
11. Practical considerations in the use of oral fluoropyrimidines.
Hoff PM
Semin Oncol; 2003 Jun; 30(3 Suppl 6):88-92. PubMed ID: 12802799
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Diasio RB
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
[TBL] [Abstract][Full Text] [Related]
13. Oral therapy for colorectal cancer: how to choose.
Damjanov N; Meropol NJ
Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632
[TBL] [Abstract][Full Text] [Related]
14. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Usuki H; Ishimura K; Yachida S; Hagiike M; Okano K; Izuishi K; Karasawa Y; Goda F; Maeta H
Gastric Cancer; 2003; 6 Suppl 1():66-70. PubMed ID: 12775023
[TBL] [Abstract][Full Text] [Related]
15. Improving 5-FU with a novel dihydropyrimidine dehydrogenase inactivator.
Diasio RB
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):51-6. PubMed ID: 9556784
[TBL] [Abstract][Full Text] [Related]
16. Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Koda K; Miyauchi H; Kosugi C; Kaiho T; Takiguchi N; Kobayashi S; Maruyama T; Matsubara H;
Anticancer Res; 2016 Oct; 36(10):5325-5331. PubMed ID: 27798895
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
18. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Schilsky RL; Kindler HL
Expert Opin Investig Drugs; 2000 Jul; 9(7):1635-49. PubMed ID: 11060767
[TBL] [Abstract][Full Text] [Related]
19. Oral fluoropyrimidine treatment of colorectal cancer.
Eng C; Kindler HL; Schilsky RL
Clin Colorectal Cancer; 2001 Aug; 1(2):95-103. PubMed ID: 12445367
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
